GHP / April 2017 3 Editor’s Note , Welcome to the April edition of Global Health & Pharma. In recent news, Teva Pharmaceuticals Europe BV announced the launch of ‘Get it Right’ – an engaging, disease awareness campaign aiming to challenge the public’s and physician’s mind-set in managing asthma, through education on how to use asthma inhalers correctly. In contract news, Crawford Healthcare, the UK’s fastest growing advanced wound care company, has won a key government tender that will see its innovative wound dressings recommended as products of choice by Abu Dhabi’s public health body. We also learn more about Altogen Labs, an Austin, TX based contract research organization (CRO) founded in 2009, offering preclinical laboratory services to pharmaceutical, biotechnology and academic researchers worldwide to support and accelerate medical discovery and research studies. I hope you enjoy reading all that this edition has to offer. Jonathan Miles, Editor Phone: +44 (0) 203 725 6842 Email: jonathan.mile [email protected] Website: www.ghp-magazine.com AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.